- Report
- February 2024
- 90 Pages
Global
From €3500EUR$3,941USD£3,102GBP
- Report
- October 2022
- 94 Pages
Global
From €1903EUR$2,000USD£1,629GBP
- Drug Pipelines
- November 2020
- 143 Pages
Global
From €1903EUR$2,000USD£1,629GBP
- Report
- May 2023
- 160 Pages
Global
From €5708EUR$5,999USD£4,887GBP
- Report
- March 2023
- 147 Pages
Global
From €5708EUR$5,999USD£4,887GBP
Diabetic Neuropathy Drug is a type of Central Nervous System (CNS) drug used to treat nerve damage caused by diabetes. It works by blocking the transmission of pain signals from the nerves to the brain. Commonly used drugs include anticonvulsants, antidepressants, and opioids. These drugs can help reduce pain, improve sleep, and improve quality of life. Side effects may include drowsiness, dizziness, and nausea.
The Diabetic Neuropathy Drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of diabetes, as well as the need for effective treatments for diabetic neuropathy. The market is expected to continue to grow in the coming years, as new treatments are developed and approved.
Some companies in the Diabetic Neuropathy Drug market include Pfizer, Novartis, Merck, and GlaxoSmithKline. Show Less Read more